Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
News
A young girl with an unusual form of low-grade glioma, a type of brain tumor, responded well to standard chemotherapy, emphasizing the value of…
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
One-third of patients with hard-to-treat myeloma were alive and free from disease progression five years after a single infusion of the cell therapy Carvykti…
A team led by a Rice University researcher received a grant to investigate treatments targeting mitochondria for acute amyloid leukemia (AML), a type of…
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
Data from a clinical trial show the experimental treatment lucicebtide has so far been well tolerated in people with glioblastoma, an aggressive type of…
A committee of the European Medicines Agency has recommended approving GSK’s Blenrep (belantamab mafodotin) in combination with other therapeutic agents to treat relapsed or refractory…
The first participant in a U.S. Phase 1 clinical trial testing T-cell therapy candidate CER-1236 — Cero Therapeutics’ treatment for people with acute myeloid…
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
